Soleno shares fell double digits amid questions about the growth trajectory of its Prader-Willi drug. Elsewhere, a cancer ...

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Without taking a firm position, the antitrust agency said Novo’s two-step deal structure may illegally sidestep requirements for a premerger review.

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted developer of obesity drugs.

Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in ...

The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a ...